ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy

Inclusion Criteria: * Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study: * Subjects have a diagnosis of soft tissue sarcoma, NSCLC, HNSCC, breast, pancreatic cancer, or melanoma * For Cohort 1 (n=15), participants are eligible if starting on a new chemotherapy regimen with either: (i) high risk (\> 20%) of febrile neutropenia as per NCCN MGF guidelines; or (ii) intermediate risk for febrile neutropenia AND one or more risk factors for febrile neutropenia: * Age \> or equal to 65 years * Advanced disease * Previous Chemotherapy or Radiation therapy * Preexisting neutropenia or bone marrow involvement with tumor * Infection * Open wounds or surgery in last 4 weeks * Poor performance status or poor nutritional status * Poor renal function (cr clearance \<50) * Total Bilirubin \>1.5 upper limit of normal * Cardiovascular Disease * Multiple Co-morbidities * HIV infection * BMI \> 2.0 * For Cohort 2 (n=15) participants are eligible if starting on immunotherapy alone, or concurrent chemo-immunotherapy. * Participants are capable of giving informed consent * Participants must be able to read and/or to speak English * Participants who are 18 years of age or older * Expected chemotherapy treatment duration of at least 12 weeks Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in this study: * Participants who cannot read or speak English * Participants without any cellphone access